Related Experiment Videos
Effect of verapamil on serum lipoproteins in patients with angina pectoris
Insights
Verapamil treatment beneficially impacts serum lipoproteins by lowering LDL-cholesterol, a key atherogenic factor. This study found verapamil significantly reduced LDL-cholesterol without negatively affecting other critical lipid levels.
Area of Science:
- Cardiovascular Pharmacology
- Lipid Metabolism
Background:
- Beta-blocking agents can adversely affect atherogenic (VLDL-triglycerides) and atheroprotective (HDL-cholesterol) lipoproteins.
- The impact of verapamil, a non-beta-blocker calcium channel blocker, on serum lipoproteins requires investigation.
Purpose of the Study:
- To investigate the effects of verapamil on atherogenic LDL-cholesterol and other serum lipoproteins.
- To determine if verapamil influences lipid profiles in patients with angina pectoris or hypertension/tachyarrhythmias.
Main Methods:
- A study involving twelve patients (mean age 56 years) treated with verapamil (240-320 mg/day).
- Serum lipoprotein levels (total cholesterol, LDL-cholesterol, VLDL-triglycerides, HDL-cholesterol) were measured at baseline, 6 weeks, and 24 weeks.
- Statistical analysis was used to assess changes in lipoprotein concentrations and their correlations.
Main Results:
- Verapamil treatment significantly decreased total serum cholesterol by 9% after 6 weeks (p<0.02) and 24 weeks (p<0.01).
- This reduction was primarily driven by a 12% decrease in LDL-cholesterol (p<0.01), correlated with initial LDL levels (r=-0.73, p<0.01).
- No significant changes were observed in VLDL-triglycerides or total HDL-cholesterol; HDL3 cholesterol showed a significant increase (12%, p<0.05).
Conclusions:
- Verapamil demonstrates a beneficial effect on serum lipoproteins by lowering atherogenic LDL-cholesterol.
- Verapamil does not appear to negatively impact other key lipoproteins, including HDL-cholesterol and VLDL-triglycerides.
- These findings suggest verapamil may offer cardiovascular benefits beyond its primary therapeutic actions.
Abstract:
Since several beta-blocking agents increase the atherogenic VLDL-triglycerides and decrease the atheroprotective HDL-cholesterol we studied if verapamil also affects these lipoproteins or the most atherogenic LDL-cholesterol. Twelve patients (three females), mean age 56 years, with angina pectoris or hypertension/tachyarrhythmias were treated with verapamil 240-320 mg/day. Serum lipoproteins were measured before and after 6 and 24 weeks of therapy. Initial total serum cholesterol averaged 7.27 mmol/l. After 6 weeks of treatment it decreased by 9%, p less than 0.02. These results remained significant, p less than 0.01 after 24 weeks. The decrease was due to a fall in LDL-cholesterol by 12%, p less than 0.01. The reduction in LDL-cholesterol was correlated to initial LDL-cholesterol concentration, r = -0.73, p less than 0.01. Within LDL there was a parallel decrease in phospholipids, p less than 0.05. There were no changes in total or VLDL-triglycerides or total HDL-cholesterol. In the HDL fraction HDL2 decreased insignificantly but HDL3 cholesterol increased by 12%, p less than 0.05. We conclude that verapamil has a beneficial effect on serum lipoproteins in that it lowers the atherogenic LDL-cholesterol and does not affect the other lipoproteins in an undesirable way.